High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion
- 2 August 2007
- journal article
- Published by Wiley in Transfusion
- Vol. 47 (11), 1972-1983
- https://doi.org/10.1111/j.1537-2995.2007.01420.x
Abstract
Human cytomegalovirus (CMV) is considered to latently infect blood cells. Transfusion-transmitted infection (TT-CMV) of immunocompromised patients occurs despite the use of CMV-seronegative or leukoreduced units. The prevalence of CMV DNA in plasma was investigated in 82 blood donors who had previously been seronegative for CMV and showed anti-CMV immunoglobulin G for the first time, 598 blood donors who were seropositive for at least 1 year, and 150 seronegative blood donors. In a second part of the study, the overall prevalence of CMV DNA in blood donations was assessed based on 31,745 donations. CMV DNA was repeatedly detected in plasma samples of 44 percent of newly seropositive donors (12%-62%, depending on the interval to the last seronegative donation). All steadily seropositive or seronegative donors were negative for the presence of CMV DNA. Detection of CMV DNA in connection with seroconversion was accompanied by significantly increased neopterin, increased alanine aminotransferase, and reduced white blood cell counts, but the sensitivity of these surrogate markers was only 71 percent. The overall prevalence of CMV DNA in blood products due to primary CMV infection of donors was at least 0.13 percent. Viremia of newly seropositive donors may be an important reason for the residual risk of TT-CMV despite leukoreduction. Furthermore, transfusion of WBC-reduced blood components from seronegative donors could imply a greater risk of TT-CMV than transfusion of WBC-reduced blood from donors who have been seropositive for at least 1 year, because window-phase donations but no reactivation could be detected in this study.Keywords
This publication has 56 references indexed in Scilit:
- Transfusion of leukoreduced cellular blood components from cytomegalovirus-unscreened donors in allogeneic hematopoietic transplant recipients: analysis of 72 recipientsBone Marrow Transplantation, 2005
- Hay fever and a single intramuscular injection of corticosteroid: a systematic reviewPrimary Care Respiratory Journal, 2005
- Alanine aminotransferase cut‐off values for blood donor screening using the new International Federation of Clinical Chemistry reference method at 37 °CVox Sanguinis, 2003
- Cytomegalovirus Studies on Blood Donors in North‐East Scotland and a Review of UK DataVox Sanguinis, 1993
- Prevention of transfusion‐associated cytomegalovirus infection in neonatal patients by the removal of white cells from bloodTransfusion, 1992
- Prevention of primary cytomegalovirus infection in patients with hematologic malignancies by intensive white cell depletion of blood productsTransfusion, 1989
- USE OF LEUCOCYTE‐POOR BLOOD COMPONENTS TO PREVENT PRIMARY CYTOMEGALOVIRUS (CMV) INFECTION IN PATIENTS WITH ACUTE LEUKAEMIABritish Journal of Haematology, 1988
- Prevention of Transfusion-Associated Cytomegalovirus (CMV) Infection in Neonates by Screening Blood Donors for IgM to CMVThe Journal of Infectious Diseases, 1988
- Cytomegalovirus Immune Globulin and Seronegative Blood Products to Prevent Primary Cytomegalovirus Infection after Marrow TransplantationThe New England Journal of Medicine, 1986
- Prevention of transfusion-acquired cytomegalovirus infections in newborn infantsThe Journal of Pediatrics, 1981